Latest From ChemoCentryx Inc.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.
Switzerland’s leader in iron deficiency therapies wants to add new products in this and adjacent therapeutic areas, as strong revenue growth in 2018 backs its strategy of concentrating its efforts on the pharmaceuticals business.
With just three marketing applications filed, the European Medicines Agency says it is too soon to say whether PRIME, its priority medicines scheme, is meeting its objective. The agency is satisfied, though, that the scheme has started to drive innovation.
- Drug Discovery Tools
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- North America
- Parent & Subsidiaries
- ChemoCentryx Inc.
- Senior Management
Thomas J Schall, PhD, Pres. & CEO
Susan M Kanaya, EVP, CFO & Chief Administrative Officer
Markus J Cappel, PhD, CBO
William Fairey, EVP, COO
- Contact Info
Phone: (650) 210-2900
850 Maude Ave.
Mountain View, CA 94043
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.